Get the Stockscreener App
2.56
4.92%
0.12
After Hours:
2.40
-0.16
-6.25%
Prelude Therapeutics Inc stock is traded at $2.56, with a volume of 208.40K.
It is up +4.92% in the last 24 hours and up +75.34% over the past month.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
See More
Previous Close:
$2.44
Open:
$2.48
24h Volume:
208.40K
Relative Volume:
0.16
Market Cap:
$160.94M
Revenue:
-
Net Income/Loss:
$-131.52M
P/E Ratio:
-1.4382
EPS:
-1.78
Net Cash Flow:
$-107.56M
1W Performance:
-9.86%
1M Performance:
+75.34%
6M Performance:
+222.46%
1Y Performance:
+92.48%
1-Day Range:
$2.41
$2.64
1-Week Range:
$2.3704
$2.95
52-Week Range:
$0.6101
$4.22
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Name
Prelude Therapeutics Inc
Sector
Industry
Phone
(302) 467-1280
Address
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
2.56 | 153.39M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-20-24 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-13-24 | Initiated | JMP Securities | Mkt Outperform |
| Feb-20-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-29-22 | Initiated | Jefferies | Buy |
| Mar-15-22 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-28-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-27-21 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-26-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Nov-20-20 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Goldman | Neutral |
| Oct-20-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prelude Therapeutics Inc Stock (PRLD) Latest News
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Up 28.5% in December - MarketBeat
Bullish Prelude Therapeutics Insiders Rewarded As Their Investment Rises To US$2.75m - Sahm
Prelude Therapeutics Incorporated's (NASDAQ:PRLD) Path To Profitability - Yahoo Finance
Prelude Therapeutics (NASDAQ:PRLD) Stock Price Up 2.1%What's Next? - MarketBeat
How Prelude Therapeutics Incorporated stock compares to industry benchmarksJuly 2025 Retail & Step-by-Step Trade Execution Guides - Улправда
What dividend safety score for Prelude Therapeutics Incorporated stock2025 Key Lessons & Risk Controlled Swing Alerts - Улправда
How Prelude Therapeutics Incorporated stock responds to policy changesEarnings Overview Summary & Scalable Portfolio Growth Methods - Улправда
Risk Analysis: What technical signals suggest for Prelude Therapeutics Incorporated stockForecast Cut & High Yield Stock Recommendations - Улправда
Is Prelude Therapeutics Incorporated stock a buy before product launches2025 Price Action Summary & Technical Pattern Based Signals - Улправда
Trend Report: Can Prelude Therapeutics Incorporated stock resist market sell offsJuly 2025 Setups & Free High Return Stock Watch Alerts - Улправда
Is Prelude Therapeutics Incorporated stock positioned well for digital economyPrice Action & Technical Confirmation Alerts - DonanımHaber
Is Prelude Therapeutics Incorporated stock overvalued by current metricsVolume Spike & Long-Term Investment Growth Plans - DonanımHaber
Will Prelude Therapeutics Incorporated stock reach all time highs in 2025Earnings Recap Report & Smart Swing Trading Techniques - DonanımHaber
Will Prelude Therapeutics Incorporated stock pay special dividends2025 Dividend Review & Daily Profit Maximizing Tips - DonanımHaber
Can Prelude Therapeutics Incorporated stock sustain revenue growthJuly 2025 News Drivers & Fast Gain Swing Trade Alerts - DonanımHaber
Why Prelude Therapeutics Incorporated stock attracts global investors2025 Dividend Review & Daily Profit Maximizing Tips - Bölüm Sonu Canavarı
What technical signals suggest for Prelude Therapeutics Incorporated stockJuly 2025 EndofMonth & Weekly Return Optimization Plans - Улправда
Is Prelude Therapeutics Incorporated stock a buy for dividend growthJuly 2025 Closing Moves & Weekly Top Gainers Trade List - Улправда
Prelude Therapeutics Earnings Notes - Trefis
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards - GlobeNewswire
Prelude Therapeutics divulges new JAK2 inhibitors - BioWorld MedTech
It makes sense and dollars to buy Prelude Therapeutics Inc (PRLD) stock - setenews.com
Prelude Therapeutics presents data at 2025 ASH meeting from MPN programs - MSN
Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens - Investing.com Canada
Prelude Therapeutics (PRLD) Reveals Promising Preclinical Data a - GuruFocus
Prelude Therapeutics Unveils Promising Preclinical Data for JAK2V617F-selective JH2 Inhibitor and mCALR-targeted Degrader Antibody Conjugate at ASH 2025 - Quiver Quantitative
Prelude Therapeutics Presents Data at the 2025 ASH Annual - GlobeNewswire
Prelude Therapeutics (Nasdaq: PRLD) details MPN pipeline at 2025 ASH, eyes 2026 IND - Stock Titan
What insider trading reveals about Prelude Therapeutics Incorporated stockShort Setup & Daily Volume Surge Trade Alerts - Newser
Penny Stocks To Consider In December 2025 - simplywall.st
VIX Spike: How Prelude Therapeutics Incorporated stock compares to industry benchmarksJuly 2025 Decliners & Growth Focused Stock Pick Reports - moha.gov.vn
Growth Report: What dividend safety score for Prelude Therapeutics Incorporated stockJuly 2025 Big Picture & Daily Volume Surge Signals - moha.gov.vn
PRLD Investors Have Opportunity to Join Prelude - GlobeNewswire
This trade activity should not be overlooked: Prelude Therapeutics Inc (PRLD) - Setenews
Beat the Market the Zacks Way: Goldman Sachs, Micron, Prelude in Focus - TradingView — Track All Markets
Prelude Therapeutics Experiences Revision in Its Stock Evaluation Amid Mixed Financial Trends - Markets Mojo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics IncorporatedPRLD - PR Newswire
Will Prelude Therapeutics Incorporated stock outperform Dow Jones indexJuly 2025 Sentiment & Smart Money Movement Alerts - newser.com
Is Prelude Therapeutics Incorporated stock supported by innovation pipeline2025 Volume Leaders & Free High Return Stock Watch Alerts - newser.com
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation ... - Bakersfield.com
Prelude Therapeutics Incorporated (PRLD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What to do if you’re stuck in Prelude Therapeutics IncorporatedPortfolio Update Summary & Smart Investment Allocation Insights - newser.com
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B - GlobeNewswire
Is Prelude Therapeutics Incorporated stock ready for a breakoutJuly 2025 Sector Moves & Weekly Market Pulse Updates - newser.com
What sentiment indicators say about Prelude Therapeutics Incorporated stock2025 Valuation Update & Safe Capital Growth Stock Tips - newser.com
Prelude Advances Two Novel Cancer Programs as Cash Runway Extends Into 2027 - MyChesCo
Order flow analysis tools used on Prelude Therapeutics IncorporatedJuly 2025 Sector Moves & Daily Volume Surge Signals - newser.com
Can Prelude Therapeutics Incorporated stock hit analyst price targets2025 Geopolitical Influence & Fast Entry Momentum Trade Alerts - newser.com
Real time alert setup for Prelude Therapeutics Incorporated performanceProduct Launch & Safe Entry Trade Signal Reports - newser.com
Is Prelude Therapeutics Incorporated stock supported by strong fundamentalsJuly 2025 Market Mood & Weekly Breakout Stock Alerts - newser.com
Century Therapeutics Unveils iPSC Beta Islet Program as Cash Runway Extends Into 2027 - MyChesCo
Prelude Therapeutics Inc Stock (PRLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prelude Therapeutics Inc Stock (PRLD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Vaddi Krishna | CEO |
Mar 25 '25 |
Buy |
0.69 |
675,000 |
467,438 |
1,999,296 |
| Vaddi Krishna | CEO |
Mar 21 '25 |
Buy |
0.73 |
15,000 |
10,959 |
1,324,296 |
| Vaddi Krishna | CEO |
Mar 20 '25 |
Buy |
0.73 |
5,416 |
3,950 |
1,309,296 |
| Vaddi Krishna | CEO |
Mar 14 '25 |
Buy |
0.75 |
29,999 |
22,631 |
1,294,774 |
| Vaddi Krishna | CEO |
Mar 17 '25 |
Buy |
0.75 |
9,106 |
6,829 |
1,303,880 |
| Vaddi Krishna | CEO |
Mar 13 '25 |
Buy |
0.72 |
50,000 |
35,820 |
1,264,775 |
| Vaddi Krishna | CEO |
Mar 12 '25 |
Buy |
0.71 |
47,500 |
33,744 |
1,214,775 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):